Antibody-armored dendritic cell therapy for people with solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1, single-arm, open-label, single-administration dose-escalation trial of an antibody-armored dendritic cell product in adults with histologically confirmed solid tumors who have completed at least four cycles of postoperative adjuvant chemotherapy. Eligible participants must have undergone R0 or R1 resection and show positive expression for at least one of TERT, P53, KRAS or Survivin, with ECOG 0–1 and adequate organ and bone marrow function. The intervention involves collecting peripheral blood mononuclear cells, manufacturing the armored dendritic cells, and delivering a single injection while closely monitoring for safety and dose-limiting toxicities. Secondary observations will likely include immune response measures and preliminary signals of recurrence prevention.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Aged 18 to 80 years, body weight ≥ 40 kg; male or female, no gender restriction;
* ECOG performance status score of 0 to 1;
* Histopathologically confirmed solid tumors including pancreatic cancer, colorectal cancer (CRC), gastric cancer and other such malignancies;
* Having undergone R0 or R1 resection with completion of at least 4 cycles of standard postoperative adjuvant chemotherapy;
* Positive expression for at least one of TERT, P53, KRAS and Survivin;
* Sufficient venous access with no contraindications to peripheral blood mononuclear cell collection;
* Adequate organ and bone marrow function:
* a) Platelet count ≥ 90×10⁹/L;
* b) Hemoglobin ≥ 90 g/L (no blood transfusion or erythropoietin dependence within 7 days);
* c) Mononuclear cell count ≥ 1.0×10⁹/L;
* d) International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × upper limit of normal (ULN);
* e) Serum creatinine ≤ 1.5 × upper limit of normal (ULN);
* f) Aminotransferases (AST, ALT) ≤ 2.5 × upper limit of normal (ULN);
* g) Total bilirubin ≤ 2 × upper limit of normal (ULN);
* h) Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as assessed by echocardiography within 1 month prior to enrollment;
* Able to understand the study requirements and considerations and provide informed consent to participate in the clinical study in accordance with the study requirements
* Subjects agree to use effective contraceptive measures for at least 6 months following dendritic cell (DC) injection.

Exclusion Criteria:

* Women who are pregnant or breastfeeding;
* Positive for human immunodeficiency virus (HIV) antibody or syphilis antibody; positive for hepatitis B surface antigen (HBsAg), positive for hepatitis B core antibody (anti-HBc) or hepatitis B e antibody (anti-HBe) with hepatitis B virus (HBV) DNA copy number above the lower limit of detection (LLOD) or ≥ 1000 copies/mL; or hepatitis C virus (HCV) RNA copy number above the LLOD;
* Prior treatment with any dendritic cell (DC) or other immune cell therapy;
* History of hypersensitivity to immunotherapy and related drugs, or history of severe allergic reactions;
* Uncontrolled active infection;
* Subjects with active autoimmune disease receiving relevant treatment; subjects with organ transplantation who are still on immunosuppressive agents; or subjects requiring long-term use of immunosuppressive agents (\> 15 mg/day prednisone or equivalent glucocorticoid dose) and who have used them within 4 weeks prior to screening;
* Presence of central nervous system (CNS) metastases and clinically significant CNS diseases;
* Received systemic anti-tumor therapy within 4 weeks prior to screening;
* Presence of residual lesions or unremoved foci on screening examinations (post-adjuvant chemotherapy / post-surgery), with imaging indicating local recurrence or confirmed distant metastasis;
* History of other active malignancies within 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.);
* Clinically significant major cardiovascular diseases including:
* a) Symptomatic congestive heart failure
* b) Unstable angina pectoris
* c) Severe arrhythmia requiring pharmacotherapy
* d) Uncontrolled hypertension
* e) Myocardial infarction or ventricular arrhythmia within 6 months prior to screening;
* Any other conditions deemed by the investigator to render the subject ineligible for participation in the clinical study

Where it's running

• Shanghai Mengchao Tumor Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Xu Qing
• Email: xuqing@shcell.com
• Phone: 13761325567

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adjuvant sintilimab after neoadjuvant therapy and surgery for high-risk NSCLC

  This trial tests whether giving sintilimab after surgery helps prevent cancer from returning in people with high-risk non-small cell lung cancer who already had neoadjuvant immunochemotherapy and surgery.

  Recruiting at 2 sites Phase 2 Sichuan University · Chengdu, Sichuan and 1 other locations · NCT07748325

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Using a weighted blanket to help cancer patients during IV therapy

  A randomized study tests whether wearing a weighted blanket during IV cancer treatment reduces anxiety, stress, and depression and increases comfort compared with standard blankets.

  Recruiting Sultan Qaboos Comprehensive Cancer Center · Muscat, Seeb · NCT07653035

• Maintenance with QL1706 after chemo in high-risk triple-negative breast cancer

  This study tests whether adding QL1706 after standard chemotherapy can help people with high-risk triple-negative breast cancer stay cancer-free longer.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT07622836

• JY016 injection for EGFR-positive advanced solid tumors

  This study tests JY016 injections in adults with EGFR-expressing advanced solid cancers to see if it is safe and potentially effective.

  Recruiting Phase 1/2 Biotech Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07510841

• Biomarkers and immune responses in early-stage solid cancers treated with immunotherapy

  This study tests immune biomarkers in patients with early-stage solid cancers who are receiving immune checkpoint blockade before surgery.

  Recruiting Institut Claudius Regaud · Toulouse and 2 other locations · NCT07427186

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.